Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AKRO

Akero Therapeutics Inc

Nov 30 • 11:59AM ET

16.65

Dollar change -0.01
Percentage change -0.09	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	14.20%	Shs Outstand	55.71M	Perf Week	4.42%
Market Cap	927.29M	Forward P/E	-	EPS next Y	-3.62	Insider Trans	-3.56%	Shs Float	47.80M	Perf Month	39.64%
Income	-119.63M	PEG	-	EPS next Q	-0.83	Inst Own	98.64%	Short Float / Ratio	12.87% / 3.30	Perf Quarter	-66.46%
Sales	0.00M	P/S	-	EPS this Y	2.50%	Inst Trans	26.33%	Short Interest	6.15M	Perf Half Y	-63.11%
Book/sh	10.47	P/B	1.59	EPS next Y	-29.29%	ROA	-23.58%	Target Price	42.88	Perf Year	-63.67%
Cash/sh	9.96	P/C	1.67	EPS next 5Y	-14.60%	ROE	-25.82%	52W Range	11.25 - 58.38	Perf YTD	-69.63%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-19.72%	52W High	-71.49%	Beta	-0.52
Dividend %	-	Quick Ratio	20.25	Sales past 5Y	0.00%	Gross Margin	-	52W Low	47.96%	ATR	1.17
Employees	38	Current Ratio	20.25	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	46.18	Volatility	5.10% 6.65%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	22.43%	Profit Margin	-	Rel Volume	0.25	Prev Close	16.66
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Nov 13 BMO	Payout	-	Avg Volume	1.87M	Price	16.65
Recom	1.00	SMA20	10.04%	SMA50	-29.50%	SMA200	-58.27%	Volume	194,096	Change	-0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

Nov-14-23 07:21PM	Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-13-23 07:00AM	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 08:57AM	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Nov-08-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Oct-17-23 04:05PM	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference (GlobeNewswire)
04:38PM	Loading…
Oct-12-23 04:38PM	Why Akero Therapeutics Shares Are Slumping This Week (Motley Fool)
08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 05:35PM	Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward (Benzinga) -17.13%
11:11AM	Akero (AKRO) Slumps 63% on Mixed Results From NASH Study (Zacks)
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -62.61%
04:03PM	Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio (Investor's Business Daily)
12:10PM	PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023 (Associated Press Finance)
11:44AM	Why Akero Therapeutics Stock Is Crashing Today (Motley Fool)
10:37AM	Akero Therapeutics, Palantir, Hyatt Hotels: Trending tickers (Yahoo Finance Video)
09:29AM	Why Is Akero Therapeutics (AKRO) Stock Down 58% Today? (InvestorPlace)
07:15AM	Loading…
07:15AM	Akero's drug for fatty liver disease misses main trial goal (Reuters)
07:00AM	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins (GlobeNewswire)
Oct-09-23 04:05PM	Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH (GlobeNewswire)
Oct-05-23 07:01AM	Insider Sell: Akero Therapeutics Inc CEO Andrew Cheng Sells 25,000 Shares (GuruFocus.com)
Oct-04-23 08:00AM	Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 07:56AM	Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA (Zacks)
Aug-31-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in September (GlobeNewswire)
Aug-28-23 07:00AM	Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 (GlobeNewswire)
Aug-11-23 06:00AM	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +6.59%
Jul-11-23 09:02AM	Infinity Pharma (INFI) Stock Up on Advancing Cancer Study (Zacks)
Jul-10-23 09:32AM	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why (Zacks)
09:29AM	Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand (Zacks)
08:58AM	Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study (Zacks)
08:00AM	Loading…
Jul-07-23 08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-03-23 11:20AM	Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune (Zacks)
10:25AM	Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date (Zacks)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 10:04AM	Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe (Zacks)
09:59AM	Axsome (AXSM) Down on Public Offering of Common Stock (Zacks)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-28-23 10:53AM	Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks) -9.17%
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
10:36AM	Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate (Zacks)
08:50AM	Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why (Zacks)
08:21AM	Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata (Zacks)
06:41AM	Daily Vickers Top Buyers & Sellers for 06/26/2023 (Argus Research)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks)
09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
07:00AM	Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology (GlobeNewswire)
Jun-22-23 09:18AM	Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate (Zacks)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
10:46AM	Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal (Zacks)
Jun-20-23 08:54AM	Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly (Zacks)
Jun-19-23 10:28AM	Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS (Zacks)
10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:17PM	Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer (Zacks)
11:48AM	Recursion (RXRX) Up on Completing REC-994 Study Enrollment (Zacks)
09:26AM	Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)
09:18AM	Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.43%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-08-23 11:49AM	Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001 (Zacks)
11:20AM	AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System (Zacks)
Jun-07-23 12:31PM	Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View (Zacks)
08:50AM	Akero Therapeutics, Inc. (AKRO) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-06-23 01:13PM	Top Small-Cap Stocks for June 2023 (Investopedia)
12:13PM	Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails (Zacks)
11:14AM	Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study (Zacks)
Jun-05-23 12:43PM	BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody (Zacks) +11.32%
11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)
07:39AM	UPDATE 2-Akero says NASH drug shown to reduce liver fat by 65% in some patients (Reuters)
07:14AM	Akero's NASH drug reduces liver fat by 65% in some patients (Reuters)
07:00AM	Akero Therapeutics Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease (GlobeNewswire)
Jun-02-23 11:36AM	Insider Buying Alert: These 10 Stocks are Seeing Significant Insider Activity (Insider Monkey)
07:12AM	Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies (Zacks)
Jun-01-23 04:05PM	Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1 (GlobeNewswire)
May-31-23 10:46AM	J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH (Zacks)
08:00AM	Akero Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 10:56AM	Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval (Zacks)
May-29-23 07:48AM	AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal (Zacks)
May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
May-24-23 08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-23-23 09:55AM	How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22% (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
May-16-23 06:53PM	Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:33AM	We're Interested To See How Akero Therapeutics (NASDAQ:AKRO) Uses Its Cash Hoard To Grow (Simply Wall St.)
May-15-23 07:00AM	Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-10-23 08:50AM	Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going (Zacks)
May-04-23 09:21AM	Why Earnings Season Could Be Great for Akero Therapeutics (AKRO) (Zacks)
06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
Apr-18-23 09:55AM	Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-29-23 04:01PM	Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH (GlobeNewswire) +5.17%
Mar-22-23 04:09PM	Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up (Investor's Business Daily)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Jonathan	Chief Operating Officer	Nov 17	Sale	14.68	30,000	440,259	153,177	Nov 21 05:30 PM
Cheng Andrew	President and CEO	Oct 02	Option Exercise	6.36	25,000	159,000	485,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02	Option Exercise	21.10	490	10,339	183,667	Oct 04 08:33 PM
Cheng Andrew	President and CEO	Oct 02	Sale	47.91	25,000	1,197,827	460,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02	Sale	51.10	490	25,039	183,177	Oct 04 08:33 PM
Yale Catriona	Chief Development Officer	Sep 21	Option Exercise	6.36	5,000	31,800	51,010	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 21	Sale	48.07	5,000	240,356	46,010	Sep 25 08:31 PM
Graham G. Walmsley	Director	Sep 19	Buy	26.00	400,000	10,400,000	400,000	May 23 09:55 PM
Cheng Andrew	President and CEO	Sep 13	Sale	50.34	1,682	84,672	460,998	Sep 25 08:36 PM
White William Richard	Chief Financial Officer	Sep 13	Sale	50.34	632	31,815	18,468	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 13	Sale	50.34	617	31,060	46,010	Sep 25 08:31 PM
Young Jonathan	Chief Operating Officer	Sep 13	Sale	50.34	562	28,291	183,177	Sep 25 08:28 PM
Rolph Timothy	Chief Scientific Officer	Sep 13	Sale	50.34	531	26,731	150,689	Sep 25 08:30 PM
Cheng Andrew	President and CEO	Sep 01	Option Exercise	6.36	25,000	159,000	487,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Sep 01	Sale	49.77	25,000	1,244,248	462,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Aug 30	Option Exercise	0.61	15,000	9,225	462,680	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28	Option Exercise	6.36	5,745	36,538	52,372	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28	Sale	49.99	5,745	287,191	46,627	Aug 30 07:04 PM
Graham G. Walmsley	Director	Aug 08	Buy	42.06	25,000	1,051,475	600,000	Aug 10 04:46 PM
Cheng Andrew	President and CEO	Aug 01	Option Exercise	6.36	25,000	159,000	472,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Aug 01	Buy	43.26	25,000	1,081,525	575,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Aug 01	Sale	43.15	25,000	1,078,867	447,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Jul 28	Buy	42.69	30,000	1,280,709	550,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Jul 03	Option Exercise	6.36	25,000	159,000	472,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jul 03	Sale	44.88	25,000	1,122,041	447,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jun 27	Option Exercise	0.61	40,000	24,600	447,680	Jun 27 07:12 PM
Yale Catriona	Chief Development Officer	Jun 23	Sale	50.76	11,000	558,360	46,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 22	Sale	52.18	11,000	573,935	57,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 21	Sale	52.26	11,349	593,095	68,627	Jun 23 08:06 PM
White William Richard	Chief Financial Officer	Jun 20	Option Exercise	7.01	17,500	122,658	39,877	Jun 22 05:20 PM
White William Richard	Chief Financial Officer	Jun 20	Sale	55.00	20,777	1,142,735	19,100	Jun 22 05:20 PM
Heyman Tomas J.	Director	Jun 16	Option Exercise	25.04	26,000	651,040	26,000	Jun 21 05:54 PM
Henderson Jane	Director	Jun 16	Option Exercise	7.01	40,000	280,400	40,000	Jun 21 05:47 PM
Rolph Timothy	Chief Scientific Officer	Jun 16	Option Exercise	0.61	40,000	24,400	229,420	Jun 21 05:46 PM
Rolph Timothy	Chief Scientific Officer	Jun 16	Sale	54.78	78,200	4,284,066	151,220	Jun 21 05:46 PM
Henderson Jane	Director	Jun 16	Sale	54.17	40,000	2,166,685	0	Jun 21 05:47 PM
Heyman Tomas J.	Director	Jun 16	Sale	54.67	26,000	1,421,529	0	Jun 21 05:54 PM
Cheng Andrew	President & CEO	Jun 13	Sale	55.16	1,613	88,973	407,680	Jun 15 09:38 PM
White William Richard	Chief Financial Officer	Jun 13	Sale	55.16	606	33,427	22,377	Jun 15 09:41 PM
Yale Catriona	Chief Development Officer	Jun 13	Sale	55.16	591	32,600	79,976	Jun 15 09:29 PM
Young Jonathan	Chief Operating Officer	Jun 13	Sale	55.16	538	29,676	183,739	Jun 15 09:35 PM
Rolph Timothy	Chief Scientific Officer	Jun 13	Sale	55.16	509	28,076	189,420	Jun 15 09:35 PM
Cheng Andrew	President and CEO	Jun 01	Option Exercise	1.46	25,000	36,459	434,293	Jun 05 06:23 PM
Cheng Andrew	President and CEO	Jun 01	Sale	45.10	25,000	1,127,430	409,293	Jun 05 06:23 PM
Graham G. Walmsley	Director	May 19	Buy	42.00	120,000	5,040,000	520,000	May 23 09:55 PM
Cheng Andrew	President & CEO	May 01	Option Exercise	0.61	25,000	15,375	434,293	May 03 08:28 PM
Cheng Andrew	President & CEO	May 01	Sale	45.07	25,000	1,126,860	409,293	May 03 08:28 PM
Cheng Andrew	President & CEO	Apr 18	Option Exercise	0.61	40,000	24,600	409,293	May 03 08:28 PM
Cheng Andrew	President & CEO	Apr 03	Option Exercise	0.61	25,000	15,375	394,293	Apr 05 04:55 PM
Cheng Andrew	President & CEO	Apr 03	Sale	37.94	25,000	948,576	369,293	Apr 05 04:55 PM
Cheng Andrew	President & CEO	Mar 01	Option Exercise	0.61	25,000	15,375	395,999	Mar 03 04:21 PM
Cheng Andrew	President & CEO	Mar 01	Sale	46.65	25,000	1,166,338	370,999	Mar 03 04:21 PM
Cheng Andrew	President & CEO	Feb 01	Option Exercise	0.61	25,000	15,375	395,999	Feb 03 05:25 PM
Cheng Andrew	President & CEO	Feb 01	Sale	49.06	25,000	1,226,395	370,999	Feb 03 05:25 PM
Yale Catriona	Chief Development Officer	Jan 13	Sale	50.53	5,000	252,651	81,268	Jan 18 05:30 PM
Cheng Andrew	President & CEO	Jan 03	Option Exercise	0.61	25,000	15,375	395,999	Jan 05 06:46 PM
Young Jonathan	Chief Operating Officer	Jan 03	Option Exercise	0.61	8,777	5,398	193,688	Jan 05 05:56 PM
Cheng Andrew	President & CEO	Jan 03	Sale	51.27	25,000	1,281,751	370,999	Jan 05 06:46 PM
Young Jonathan	Chief Operating Officer	Jan 03	Sale	54.64	8,777	479,560	184,911	Jan 05 05:56 PM
Rolph Timothy	Chief Scientific Officer	Dec 29	Option Exercise	28.35	7,816	221,584	210,848	Dec 30 04:26 PM
Rolph Timothy	Chief Scientific Officer	Dec 29	Sale	51.05	20,316	1,037,119	190,532	Dec 30 04:26 PM
Rolph Timothy	Chief Scientific Officer	Dec 28	Option Exercise	28.35	1,700	48,195	204,732	Dec 30 04:26 PM
White William Richard	Chief Financial Officer	Dec 28	Option Exercise	7.01	999	7,002	24,623	Dec 29 05:41 PM
Rolph Timothy	Chief Scientific Officer	Dec 28	Sale	50.00	1,700	85,006	203,032	Dec 30 04:26 PM
White William Richard	Chief Financial Officer	Dec 28	Sale	49.76	999	49,714	23,624	Dec 29 05:41 PM
White William Richard	Chief Financial Officer	Dec 27	Option Exercise	7.01	19,001	133,178	42,625	Dec 29 05:41 PM
Young Jonathan	Chief Operating Officer	Dec 27	Option Exercise	6.03	12,500	75,352	194,949	Dec 28 06:30 PM
White William Richard	Chief Financial Officer	Dec 27	Sale	49.77	19,001	945,609	23,624	Dec 29 05:41 PM
Young Jonathan	Chief Operating Officer	Dec 27	Sale	49.57	12,500	619,609	182,449	Dec 28 06:30 PM
Cheng Andrew	President & CEO	Dec 16	Option Exercise	0.61	8,500	5,228	370,999	Dec 20 07:46 PM
Yale Catriona	Chief Development Officer	Dec 12	Sale	43.23	5,000	216,137	86,268	Dec 13 08:24 PM
Cheng Andrew	President & CEO	Dec 01	Option Exercise	0.61	10,000	6,150	320,148	Dec 02 05:52 PM
Skorpios Trust	Former 10% owner	Dec 01	Sale	43.50	1,636,000	71,166,000	3,271,829	Dec 05 04:36 PM
Cheng Andrew	President & CEO	Dec 01	Sale	46.07	10,000	460,700	310,148	Dec 02 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience